Cited by 37Ovarian function and disordersPharmacology and Obesity TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Effect of orlistat on weight loss, hormonal and metabolic profiles in women with polycystic ovarian syndrome: a randomized double-blind placebo-controlled trial

Moini, Ashraf, Kanani, Mahia, Kashani, Ladan, Hosseini, Reihaneh, Hosseini, Ladan·2015·Endocrine

Integrity signals

Registry

Crossref · 10.1007/s12020-014-0426-4

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • No significant benefits were observed in other metabolic parameters with orlistat in PCOS.

    “However, no significant benefits were observed in other metabolic parameters [170].”
  • In a randomized trial (n=86), orlistat 120 mg three times daily for three months plus lifestyle intervention was superior to placebo plus lifestyle in achieving greater percent weight loss (−6.37% vs −2.27%), greater reduction in waist-to-hip ratio (0.76 vs 0.86), and improvements in total testosterone and lipid profiles.

    “The drug plus lifestyle intervention was superior to placebo plus lifestyle in achieving greater percent weight loss (− 6.37% vs. −2.27%), greater reduction in waist-to-hip ratio (0.76 vs. 0.86), and improvements in total testosterone and lipid profiles [170].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Moini, A., Kanani, M., Kashani, L., Hosseini, R., & Hosseini, L.
Affiliations
Tehran University of Medical Sciences (IR)
Corresponding author
Hosseini, Reihaneh
Venue
Endocrine
Published
2014-10-08
Volume
49
Issue
1
Pages
286-289
ISSN
  • 0969-711X (ISSN-L)
  • 1355-008X
  • 1559-0100
OpenAlex
W2043228530
Cited by
37
References
28
Citations by year
2026: 2 · 2025: 5 · 2024: 9 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 4 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 1
FWCI
1.86
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
orlistat, polycystic ovary syndrome, weight loss, hormonal profile, metabolic profile, women, obesity
MeSH terms
Orlistat, Adult, Combined Modality Therapy, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Lactones, Obesity, Polycystic Ovary Syndrome, Testosterone, Weight Loss, Body Mass Index, Treatment Outcome, Caloric Restriction, Overweight, Metabolome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review